Professor Stephen Mackinnon

Consultant Haematologist


A world-class practitioner in bone marrow and stem cell research.

Professor Mackinnon leads the bone marrow and stem cell program at University College London. He became the clinical and academic head of department at the Royal Free Campus in 2004. His transplant department achieves world-class outcomes for patients with leukaemia and lymphoma.

His current research interests include adoptive immunotherapy and immune reconstitution following allogeneic stem cell transplantation. He has numerous publications.  

During his time at the Memorial Sloan Kettering Cancer Center in New York, Professor Mackinnon conducted groundbreaking work into making the use of donor lymphocytes less toxic.

Professional background


Professor Mackinnon attended medical school at the University of Glasgow, where he stayed on to train in Internal Medicine and Haemato-oncology.

Professor Mackinnon developed his interest in graft-versus-leukaemia reactions during a transplant fellowship at Hammersmith Hospital. In 1990 he moved to Memorial Sloan Kettering Cancer Center in New York to continue this work. He has published on a number of topics, including the use of donor-lymphocyte infusions in modulating relapse.

Services provided to HCA


Professor Mackinnon provides medical advisory services for HCA Joint Ventures. In his role, Professor Mackinnon leads interactions with hospital medical staff and the hospital leadership team to assist the hospital by providing medical advice and promote high quality, cost effective care.

In his role, he contributes to the strategy, policies and decision making regarding haematology treatments and advises HCA to ensure that care provided within the facility is appropriate and efficient. In his role, Professor Mackinnon advises on initiatives to drive clinical standards by providing professional advice on clinical governance matters and ensuring the adoption of those by colleagues in the haematology area.

Due to the re configuration of Cancer services within London and specifically in relation to the move of the NHS and remaining Private Haematology and Bone Marrow Transplant Service from the Royal Free Hospital to UCLH in December 2015, Professor Mackinnon has a key leadership and strategic role in the delivery and transition of these services to both UCLH and in particular to Harley Street at UCH.

Harley Street at UCH is working in partnership with UCLH with the development of Phase 4, a unique venture in creating a Blood Cancer Hospital for both NHS and Private patients that will open in 2018.  Harley Street at UCH aims to increase their inpatient bed capacity from 31 to 46. Professor Mackinnon in the intervening years will be instrumental in promoting Harley Street at UCH’s Haematology and BMT service and driving the business within the UK and overseas to ensure this is a successful business venture for Harley Street at UCH. Professor Mackinnon’s will advise the management team regarding the facilities, clinical standards to be achieved and Governance of the new service so that a world class Haematology and BMT service is delivered to our patients.

Professor Mackinnon is going to lead on the development of a unique treatment pathway at HCA for patients with Multiple Sclerosis. He will work alongside the General Manager providing expert advice, both clinical and from a governance perspective in developing and delivering a robust Autograft service line for patients with remitting and relapsing disease.

Professor Mackinnon has established a Haplo identical donor BMT service at UCH. This is a significant treatment pathway for our Arabic patients where the chance of identifying a fully matched donor is low, and the only chance of cure is a donor BMT. Professor Mackinnon advises the clinical team in how we can continue to improve our patients experience and clinical outcomes and this data is presented by Professor Mackinnon at overseas conferences and visits to the Middle East.

In addition, he works with medical insurance companies, GPs, other relevant local NHS contacts, and patients to educate and advise on relevant clinical updates to treatments in haematology available in the facility. Furthermore, he advises on the accuracy of literature that may be published regarding relevant services. He will also advise on how to make the patient referral smooth to reduce stress and anxiety for patients.

HCA UK is charged by doctors in return for their expertise and advice, including on how to operate safe hospital facilities delivering complex care.

All services provided under this agreement are charged to HCA UK. From January to December 2016, the total charge was £45,000.00.

HCA requires the doctors that advise us to attest that if they also practice in the NHS that they are not compromising their NHS commitments.